drugset / Trial / NCT03798119
TAF Switch in F3/4 CHB pt With Partial Response to NUC (ESTAB-AFPVR)
NaSingle-groupOpen-labelTreatment
Summary
A total of 80 adult chronic hepatitis B patients with advanced liver fibrosis (including fibrosis stage 3 and cirrhosis), who are currently on nucleot(s)ide analogs (except tenofovir alafenamide) therapy with detectable HBV DNA after 52 weeks of therapy will switch prior NUCs to TAF 25 mg/day for 96 weeks
Timeline
- Start
- 2019-02-25
- Primary completion
- 2020-08-31
- Completion
- 2021-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tenofovir alafenamide | Small molecule | 25 mg | Oral |